Minal Bhanushali, MD
Neurology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 3 carriers
- Offices
- 11
Offices
11 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: 058123 · Mills-Peninsula Medical Center · Sutter Solano Medical Center. That is not proof they admit you there this week.
Plans that list them
12 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Bhanushali’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A113308 · Current
Licensed to practise in California · since 2010 · expires 2028-03-31 · University of Mumbai, Grant Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
- Sutter Solano Medical CenterVallejo, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 61% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.272, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Sutter Solano Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 8 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.272 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.93 (0 to 1.95) · 374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.99 (0.6 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 162.36 (106.6 to 218.11) · 31 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.3 · 77 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.9 · 28 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.2 · 113 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.2 · 154 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.3 · 65 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.6 · 960 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.41) · 2,268 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 2,327 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.7 (0.38 to 5.03) · 594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 285 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.13 (0.47 to 3.78) · 581 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.1 (0 to 16.32) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.77 (3.74 to 11.8) · 275 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.72 (0.21 to 3.24) · 114 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.59 (0 to 1.48) · 1,998 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.8 · 171 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.4 · 142 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 0.8 · 131 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 33 · 162 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18 · 160 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.6 to 8.5) · 42 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10 (6.8 to 14.4) · 42 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.7 · 165 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 76 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.2 (10.6 to 18.9) · 322 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.8 to 1.6) · 84 cases | No different | Jan 2024 – Dec 2024 |
What patients said (355 patients answered, 17% of those asked)
| Cleanliness | 2 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 63% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 64% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 61% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$181,490
Medicare paid this office $181,490 for 547 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 212 | $52,369 | $154 |
| Botox | 23 | $50,507 | None |
| New patient visit (60+ min) | 107 | $20,174 | $189 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 15 | $5,202 | $137 |
| Muscle electrical test | 49 | $4,813 | $98 |
See all 16 services
| Long return visit (40+ min) | 212 | $52,369 | $154 |
| Botox | 23 | $50,507 | None |
| New patient visit (60+ min) | 107 | $20,174 | $189 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 15 | $5,202 | $137 |
| Muscle electrical test | 49 | $4,813 | $98 |
| Nerve test | 26 | $4,475 | $172 |
| Nerve test | 31 | $4,147 | $134 |
| Muscle electrical test | 37 | $2,667 | $65 |
| Return visit (30+ min) | 21 | $2,600 | $118 |
| Nerve test | 20 | $2,227 | $111 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 57 | $1,744 | $31 |
| Telehealth consultation, emergency department or initial inpatient, typically 30 minutes communicating with the patient via telehealth | 22 | $1,599 | $73 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 86 | $1,431 | $14 |
| Telehealth consultation, emergency department or initial inpatient, typically 50 minutes communicating with the patient via telehealth | 11 | $1,272 | $116 |
| Telephone or internet assessment with verbal and written report by consulting physician, 11-20 minutes | 45 | $1,237 | $27 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 17 | $469 | $26 |
Procedures Medicare counted
| Skin biopsy | 1-10 | None |
Who their Medicare patients are
547 Original Medicare patients in 2024. Average age 76 · Under 65 6% · 85 and older 18% · Women 58% · Also on Medicaid 12% · Health risk score 1.29. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 71% · Stroke 29% · Coronary heart disease 26% · Depression 25% · Diabetes 24% · Chronic kidney disease 21% · Atrial fibrillation 18% · Dementia 18% · Cancer 16% · Heart failure 14% · COPD 12%.
The office billed $632,607, Medicare allowed $240,489 and paid $181,490; for 12,875 services of 51 kinds; $56,295 of it was for drugs given in the office and $125,196 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 547 | 12,875 | 76 | 1.29 | $632,607 | $181,490 |
| 2023 | 450 | 8,711 | 77 | 1.23 | $509,940 | $155,985 |
| 2022 | 402 | 4,585 | 78 | 1.04 | $433,108 | $138,870 |
| 2021 | 375 | 3,227 | 77 | 1.21 | $347,936 | $116,861 |
| 2020 | 357 | 1,583 | 77 | 1.14 | $265,935 | $83,510 |
| 2019 | 429 | 2,471 | 77 | 1.06 | $360,886 | $107,336 |
| 2018 | 414 | 5,853 | 76 | 1.13 | $430,106 | $131,738 |
| 2017 | 360 | 3,583 | 76 | 1.12 | $326,463 | $98,379 |
| 2016 | 316 | 1,107 | 74 | 1.21 | $208,689 | $66,558 |
| 2015 | 323 | 1,110 | 75 | 1.54 | $184,290 | $59,408 |
| 2014 | 49 | 76 | 73 | 1.74 | $15,555 | $4,996 |
| 2013 | 18 | 25 | 72 | 1.64 | $6,545 | $1,860 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 17 services
| Long return visit (40+ min) | 237 | $57,281 | $156 |
| Botox | 20 | $37,508 | None |
| New patient visit (60+ min) | 98 | $18,659 | $190 |
| Measurement of brain wave activity (eeg), awake and drowsy | 15 | $6,646 | $415 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 11 | $3,052 | $133 |
| New patient visit (45+ min) | 20 | $2,884 | $144 |
| Return visit (30+ min) | 24 | $2,789 | $112 |
| Muscle electrical test | 26 | $2,332 | $90 |
| Nerve test | 19 | $2,305 | $121 |
| Nerve test | 12 | $2,078 | $173 |
| Muscle electrical test | 21 | $1,622 | $65 |
| Telehealth consultation, emergency department or initial inpatient, typically 30 minutes communicating with the patient via telehealth | 14 | $1,112 | $79 |
| Telephone medical discussion with physician, 11-20 minutes | 11 | $999 | $77 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 25 | $798 | $32 |
| Short return visit (20+ min) | 11 | $796 | $72 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 26 | $771 | $28 |
| Telephone or internet assessment with verbal and written report by consulting physician, 11-20 minutes | 15 | $411 | $27 |
2022: 11 services
| Long return visit (40+ min) | 231 | $61,124 | $155 |
| New patient visit (60+ min) | 106 | $20,737 | $196 |
| Botox | 12 | $18,130 | None |
| Measurement of brain wave activity (eeg), awake and drowsy | 27 | $11,287 | $418 |
| Return visit (30+ min) | 49 | $5,274 | $103 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 36 | $1,437 | $30 |
| Muscle electrical test | 11 | $1,138 | $103 |
| Short return visit (20+ min) | 11 | $1,048 | $87 |
| Telephone medical discussion with physician, 11-20 minutes | 12 | $988 | $71 |
| Muscle electrical test | 11 | $818 | $68 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 22 | $718 | $33 |
2021: 11 services
| Long return visit (40+ min) | 193 | $48,090 | $161 |
| New patient visit (60+ min) | 87 | $16,505 | $190 |
| Return visit (30+ min) | 80 | $10,264 | $112 |
| Measurement of brain wave activity (eeg), awake and drowsy | 15 | $6,321 | $421 |
| New patient visit (45+ min) | 21 | $3,342 | $159 |
| Nerve test | 13 | $1,905 | $147 |
| Muscle electrical test | 13 | $1,354 | $71 |
| Short return visit (20+ min) | 15 | $1,245 | $83 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 23 | $892 | $31 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 22 | $725 | $33 |
| Telephone, internet, or electronic health record assessment and management with verbal and written report by consulting physician, 5-10 minutes | 11 | $185 | $17 |
2020: 13 services
| Long return visit (40+ min) | 109 | $18,213 | $128 |
| New patient visit (60+ min) | 85 | $15,151 | $178 |
| Return visit (30+ min) | 99 | $10,880 | $91 |
| Measurement of brain wave activity (eeg), awake and drowsy | 12 | $4,809 | $401 |
| New patient visit (45+ min) | 23 | $3,351 | $146 |
| Telephone medical discussion with physician, 21-30 minutes | 23 | $2,627 | $105 |
| Short return visit (20+ min) | 33 | $2,288 | $64 |
| Telehealth consultation, emergency department or initial inpatient, typically 70 minutes or more communicating with the patient via telehealth | 12 | $2,228 | $186 |
| Nerve test | 11 | $2,120 | $193 |
| Muscle electrical test | 25 | $1,918 | $66 |
| Nerve test | 12 | $1,646 | $137 |
| Telehealth consultation, emergency department or initial inpatient, typically 30 minutes communicating with the patient via telehealth | 16 | $1,470 | $92 |
| Telephone medical discussion with physician, 11-20 minutes | 17 | $1,397 | $74 |
2019: 11 services
| Return visit (30+ min) | 179 | $23,622 | $94 |
| New patient visit (60+ min) | 131 | $23,558 | $180 |
| Long return visit (40+ min) | 98 | $14,317 | $128 |
| Measurement of brain wave activity (eeg), awake and drowsy | 19 | $7,128 | $375 |
| Measurement of brain wave activity (eeg), awake and asleep | 11 | $4,611 | $419 |
| New patient visit (45+ min) | 29 | $3,611 | $125 |
| Short return visit (20+ min) | 51 | $3,462 | $65 |
| Nerve test | 21 | $2,794 | $133 |
| Nerve test | 14 | $2,434 | $174 |
| Muscle electrical test | 25 | $2,360 | $94 |
| Muscle electrical test | 21 | $1,533 | $64 |
2018: 13 services
| New patient visit (60+ min) | 129 | $23,180 | $180 |
| Botox | 14 | $22,974 | None |
| Return visit (30+ min) | 161 | $22,225 | $93 |
| Long return visit (40+ min) | 83 | $11,774 | $127 |
| Measurement of brain wave activity (eeg), awake and drowsy | 28 | $10,753 | $384 |
| Measurement of brain wave activity (eeg), awake and asleep | 16 | $7,168 | $448 |
| New patient visit (45+ min) | 48 | $6,926 | $144 |
| Short return visit (20+ min) | 53 | $3,791 | $64 |
| Nerve test | 22 | $3,232 | $147 |
| Nerve test | 12 | $2,352 | $196 |
| Muscle electrical test | 24 | $2,187 | $91 |
| Muscle electrical test | 28 | $2,126 | $61 |
| New patient visit (30+ min) | 17 | $1,423 | $84 |
2017: 11 services
| Return visit (30+ min) | 135 | $18,386 | $97 |
| New patient visit (60+ min) | 74 | $13,739 | $186 |
| Long return visit (40+ min) | 71 | $10,701 | $129 |
| New patient visit (45+ min) | 67 | $9,841 | $147 |
| Short return visit (20+ min) | 72 | $5,812 | $65 |
| Nerve test | 22 | $3,241 | $147 |
| New patient visit (30+ min) | 31 | $3,032 | $98 |
| Nerve test | 16 | $2,973 | $186 |
| Muscle electrical test | 27 | $2,625 | $87 |
| Muscle electrical test | 27 | $1,840 | $59 |
| Nerve test | 11 | $1,463 | $122 |
2016: 15 services
| New patient visit (45+ min) | 58 | $8,662 | $149 |
| Return visit (30+ min) | 57 | $7,142 | $101 |
| New patient visit (30+ min) | 64 | $6,196 | $97 |
| Measurement of brain wave activity (eeg), awake and drowsy | 13 | $4,901 | $377 |
| Critical care, first 30-74 minutes | 23 | $4,341 | $167 |
| Long return visit (40+ min) | 28 | $3,563 | $119 |
| Short return visit (20+ min) | 41 | $3,247 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $3,140 | $79 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,107 | $155 |
| Nerve test | 17 | $2,405 | $141 |
| New patient visit (60+ min) | 12 | $2,278 | $190 |
| Nerve test | 11 | $2,048 | $186 |
| Muscle electrical test | 17 | $1,537 | $90 |
| Muscle electrical test | 18 | $1,198 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $909 | $50 |
2015: 11 services
| Critical care, first 30-74 minutes | 48 | $12,702 | $169 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 57 | $8,587 | $151 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 35 | $3,717 | $106 |
| New patient visit (45+ min) | 23 | $3,653 | $159 |
| New patient visit (30+ min) | 26 | $2,733 | $105 |
| Return visit (30+ min) | 25 | $2,672 | $99 |
| Short return visit (20+ min) | 29 | $2,506 | $72 |
| Critical care, each additional 30 minutes | 17 | $1,896 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 30 | $1,891 | $54 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $1,862 | $81 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 24 | $908 | $30 |
2014: 3 services
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 19 | $1,511 | $80 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,220 | $58 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 11 | $580 | $31 |
Drugs they prescribed that Part D paid
$242,344
Pharmacies billed $242,344 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their Part D prescriptions (42 of 1,692) in 2024. Above the middle of the specialty; the typical neurology clinician is at 0%. Long-acting opioids: 38% of their opioid prescriptions.
1,535 generic and fewer than 11 brand-name prescriptions · $242,344 in drug cost · 81 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rytary | Parkinson's | 19 | $32,115 | $1,690 |
| Nourianz | None | 12 | $23,305 | $1,942 |
| Emgality | Migraine | 23 | $23,050 | $1,002 |
| Ubrelvy | None | 14 | $13,589 | $971 |
| Nurtec Odt | None | 12 | $13,565 | $1,130 |
See all 38 drugs
| Rytary | Parkinson's | 19 | $32,115 | $1,690 |
| Nourianz | None | 12 | $23,305 | $1,942 |
| Emgality | Migraine | 23 | $23,050 | $1,002 |
| Ubrelvy | None | 14 | $13,589 | $971 |
| Nurtec Odt | None | 12 | $13,565 | $1,130 |
| Aimovig | Migraine | 13 | $10,738 | $826 |
| Emgality | Migraine | 13 | $8,748 | $673 |
| Carbidopa-Levodopa | None | 123 | $6,344 | $52 |
| Gabapentin | None | 224 | $4,973 | $22 |
| Carbidopa-Levodopa Er | None | 58 | $3,504 | $60 |
| Levetiracetam | None | 46 | $3,172 | $69 |
| Lamotrigine Er | None | 23 | $2,381 | $104 |
| Memantine | None | 52 | $1,910 | $37 |
| Donepezil | None | 128 | $1,571 | $12 |
| Quetiapine | None | 80 | $1,524 | $19 |
| Rivastigmine | None | 23 | $1,466 | $64 |
| Pregabalin | None | 65 | $1,344 | $21 |
| Primidone | None | 24 | $1,003 | $42 |
| Divalproex Sodium Er | None | 21 | $921 | $44 |
| Propranolol | None | 61 | $846 | $14 |
| Divalproex | None | 18 | $844 | $47 |
| Bupropion Xl | None | 19 | $776 | $41 |
| Baclofen | None | 38 | $764 | $20 |
| Trazodone | None | 58 | $727 | $13 |
| Duloxetine | None | 26 | $677 | $26 |
| Fludrocortisone Acetate | None | 14 | $656 | $47 |
| Rizatriptan | None | 15 | $580 | $39 |
| Escitalopram | None | 43 | $573 | $13 |
| Clopidogrel | None | 18 | $371 | $21 |
| Topiramate | None | 12 | $255 | $21 |
| Diazepam | None | 14 | $248 | $18 |
| Mirtazapine | None | 11 | $230 | $21 |
| Meloxicam | None | 16 | $176 | $11 |
| Atorvastatin | None | 20 | $165 | $8 |
| Methadone | None | 16 | $139 | $9 |
| Nortriptyline | None | 13 | $131 | $10 |
| Lorazepam | None | 25 | $117 | $5 |
| Tramadol | None | 18 | $49 | $3 |
Year by year
| 2024 | 1,692 | 326 | 3% (42) | None | $242,344 |
| 2023 | 1,578 | 327 | 2% (31) | None | $262,970 |
| 2022 | 1,615 | 297 | 1% (22) | None | $348,135 |
| 2021 | 1,394 | 279 | 2% (24) | None | $178,386 |
| 2020 | 1,198 | 256 | 2% (27) | 6% | $140,373 |
| 2019 | 1,103 | 245 | 4% (41) | None | $160,934 |
| 2018 | 1,215 | 237 | 2% (28) | 15% | $235,538 |
| 2017 | 1,037 | 206 | 1% (15) | None | $117,235 |
| 2016 | 487 | 140 | 3% (13) | None | $64,904 |
| 2015 | 309 | 108 | None | 7% | $22,300 |
| 2014 | 454 | 155 | 7% (32) | 23% | $65,711 |
| 2013 | 397 | 143 | 8% (31) | 37% | $104,813 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 32 drugs
| Rytary | Parkinson's | 15 | $39,316 | $2,621 |
| Emgality | Migraine | 28 | $28,153 | $1,005 |
| Aimovig | Migraine | 14 | $10,642 | $760 |
| Carbidopa-Levodopa | None | 101 | $5,721 | $57 |
| Gabapentin | None | 181 | $5,173 | $29 |
| Lamotrigine Er | None | 15 | $5,118 | $341 |
| Memantine | None | 62 | $3,680 | $59 |
| Rivastigmine | None | 36 | $3,666 | $102 |
| Pregabalin | None | 52 | $3,315 | $64 |
| Carbidopa-Levodopa Er | None | 51 | $3,251 | $64 |
| Donepezil | None | 149 | $2,819 | $19 |
| Quetiapine | None | 48 | $2,197 | $46 |
| Divalproex | None | 31 | $2,168 | $70 |
| Levetiracetam | None | 36 | $2,108 | $59 |
| Duloxetine | None | 37 | $1,925 | $52 |
| Fludrocortisone Acetate | None | 21 | $1,279 | $61 |
| Primidone | None | 24 | $1,234 | $51 |
| Escitalopram | None | 64 | $1,088 | $17 |
| Baclofen | None | 13 | $1,009 | $78 |
| Ropinirole | None | 14 | $1,000 | $71 |
| Propranolol | None | 50 | $983 | $20 |
| Rizatriptan | None | 26 | $928 | $36 |
| Trazodone | None | 37 | $603 | $16 |
| Lamotrigine | None | 27 | $411 | $15 |
| Lorazepam | None | 45 | $304 | $7 |
| Clopidogrel | None | 19 | $280 | $15 |
| Mirtazapine | None | 11 | $218 | $20 |
| Cyclobenzaprine | None | 23 | $145 | $6 |
| Diazepam | None | 16 | $143 | $9 |
| Atorvastatin | None | 13 | $139 | $11 |
| Methadone | None | 15 | $122 | $8 |
| Methocarbamol | None | 17 | $10 | $1 |
2022: 43 drugs
| Emgality | Migraine | 19 | $22,666 | $1,193 |
| Rytary | Parkinson's | 22 | $18,998 | $864 |
| Eliquis | None | 11 | $14,655 | $1,332 |
| Aimovig | Migraine | 17 | $13,099 | $771 |
| Lacosamide | None | 14 | $7,238 | $517 |
| Lamotrigine Er | None | 15 | $6,838 | $456 |
| Carbidopa-Levodopa | None | 77 | $6,570 | $85 |
| Gabapentin | None | 194 | $5,545 | $29 |
| Carbidopa-Levodopa Er | None | 37 | $3,632 | $98 |
| Rivastigmine | None | 40 | $3,558 | $89 |
| Sumatriptan | None | 17 | $3,165 | $186 |
| Pregabalin | None | 42 | $2,753 | $66 |
| Donepezil | None | 151 | $2,656 | $18 |
| Divalproex Sodium Er | None | 16 | $2,473 | $155 |
| Mycophenolate Mofetil | None | 17 | $1,811 | $107 |
| Duloxetine | None | 39 | $1,573 | $40 |
| Quetiapine | None | 65 | $1,523 | $23 |
| Divalproex | None | 23 | $1,516 | $66 |
| Escitalopram | None | 74 | $1,498 | $20 |
| Prednisone | None | 14 | $1,467 | $105 |
| Memantine | None | 28 | $1,399 | $50 |
| Oxcarbazepine | None | 11 | $1,381 | $126 |
| Ropinirole | None | 27 | $1,377 | $51 |
| Primidone | None | 17 | $914 | $54 |
| Rizatriptan | None | 28 | $714 | $26 |
| Propranolol | None | 40 | $697 | $17 |
| Fludrocortisone Acetate | None | 19 | $687 | $36 |
| Mirtazapine | None | 15 | $630 | $42 |
| Trazodone | None | 33 | $620 | $19 |
| Levetiracetam | None | 22 | $576 | $26 |
| Nortriptyline | None | 15 | $571 | $38 |
| Clopidogrel | None | 33 | $555 | $17 |
| Pramipexole Dihydrochloride | None | 18 | $478 | $27 |
| Baclofen | None | 12 | $468 | $39 |
| Atorvastatin | None | 42 | $364 | $9 |
| Lamotrigine | None | 15 | $364 | $24 |
| Lorazepam | None | 34 | $267 | $8 |
| Cyclobenzaprine | None | 17 | $267 | $16 |
| Oxybutynin Chloride Er | None | 11 | $266 | $24 |
| Potassium Chloride | None | 12 | $138 | $12 |
| Topiramate | None | 17 | $129 | $8 |
| Tramadol | None | 13 | $65 | $5 |
| Methocarbamol | None | 12 | $19 | $2 |
2021: 36 drugs
| Rytary | Parkinson's | 31 | $33,830 | $1,091 |
| Vimpat | None | 15 | $28,127 | $1,875 |
| Emgality | Migraine | 13 | $19,283 | $1,483 |
| Carbidopa-Levodopa | None | 89 | $9,050 | $102 |
| Pregabalin | None | 64 | $4,822 | $75 |
| Gabapentin | None | 168 | $3,470 | $21 |
| Mirtazapine | None | 15 | $2,471 | $165 |
| Donepezil | None | 113 | $2,469 | $22 |
| Rivastigmine | None | 26 | $2,340 | $90 |
| Memantine | None | 32 | $1,612 | $50 |
| Carbidopa-Levodopa Er | None | 19 | $1,319 | $69 |
| Duloxetine | None | 40 | $1,316 | $33 |
| Quetiapine | None | 51 | $1,045 | $20 |
| Escitalopram | None | 55 | $1,030 | $19 |
| Propranolol | None | 37 | $954 | $26 |
| Levetiracetam | None | 11 | $891 | $81 |
| Divalproex | None | 16 | $878 | $55 |
| Fludrocortisone Acetate | None | 13 | $810 | $62 |
| Ropinirole | None | 26 | $735 | $28 |
| Clopidogrel | None | 40 | $685 | $17 |
| Amitriptyline | None | 11 | $653 | $59 |
| Rizatriptan | None | 30 | $629 | $21 |
| Nortriptyline | None | 29 | $625 | $22 |
| Trazodone | None | 27 | $580 | $21 |
| Atorvastatin | None | 37 | $573 | $15 |
| Famotidine | None | 14 | $453 | $32 |
| Pramipexole Dihydrochloride | None | 16 | $413 | $26 |
| Lamotrigine | None | 12 | $373 | $31 |
| Clonazepam | None | 19 | $368 | $19 |
| Primidone | None | 16 | $348 | $22 |
| Oxybutynin Chloride Er | None | 13 | $345 | $27 |
| Prednisone | None | 26 | $316 | $12 |
| Topiramate | None | 18 | $163 | $9 |
| Cyclobenzaprine | None | 13 | $160 | $12 |
| Lorazepam | None | 30 | $148 | $5 |
| Tramadol | None | 14 | $30 | $2 |
2020: 33 drugs
| Emgality | Migraine | 12 | $11,721 | $977 |
| Rytary | Parkinson's | 17 | $9,610 | $565 |
| Nucynta | None | 12 | $7,900 | $658 |
| Carbidopa-Levodopa | None | 82 | $6,529 | $80 |
| Pregabalin | None | 63 | $6,298 | $100 |
| Mirtazapine | None | 27 | $3,721 | $138 |
| Gabapentin | None | 100 | $2,417 | $24 |
| Carbidopa-Levodopa Er | None | 26 | $1,800 | $69 |
| Donepezil | None | 85 | $1,321 | $16 |
| Propranolol | None | 31 | $1,286 | $41 |
| Memantine | None | 19 | $1,148 | $60 |
| Quetiapine | None | 60 | $1,084 | $18 |
| Rivastigmine | None | 17 | $1,072 | $63 |
| Amitriptyline | None | 15 | $1,003 | $67 |
| Levetiracetam | None | 21 | $906 | $43 |
| Duloxetine | None | 26 | $873 | $34 |
| Trazodone | None | 42 | $759 | $18 |
| Fludrocortisone Acetate | None | 14 | $689 | $49 |
| Escitalopram | None | 37 | $655 | $18 |
| Clopidogrel | None | 37 | $652 | $18 |
| Atorvastatin | None | 36 | $611 | $17 |
| Oxybutynin Chloride Er | None | 13 | $536 | $41 |
| Lamotrigine | None | 17 | $527 | $31 |
| Nortriptyline | None | 23 | $437 | $19 |
| Pramipexole Dihydrochloride | None | 15 | $391 | $26 |
| Rizatriptan | None | 16 | $386 | $24 |
| Topiramate | None | 14 | $336 | $24 |
| Ropinirole | None | 17 | $312 | $18 |
| Prednisone | None | 15 | $255 | $17 |
| Primidone | None | 12 | $250 | $21 |
| Clonazepam | None | 12 | $185 | $15 |
| Lorazepam | None | 33 | $107 | $3 |
| Tramadol | None | 12 | $21 | $2 |
2019: 32 drugs
| Lyrica | None | 32 | $30,410 | $950 |
| Nucynta | None | 12 | $5,648 | $471 |
| Rytary | Parkinson's | 16 | $5,595 | $350 |
| Carbidopa-Levodopa | None | 76 | $4,736 | $62 |
| Gabapentin | None | 121 | $3,886 | $32 |
| Pregabalin | None | 15 | $3,245 | $216 |
| Mirtazapine | None | 40 | $2,727 | $68 |
| Carbidopa-Levodopa Er | None | 35 | $2,346 | $67 |
| Memantine | None | 21 | $1,413 | $67 |
| Donepezil | None | 60 | $1,231 | $21 |
| Atorvastatin | None | 40 | $1,020 | $26 |
| Duloxetine | None | 28 | $1,007 | $36 |
| Quetiapine | None | 52 | $748 | $14 |
| Propranolol | None | 32 | $743 | $23 |
| Levetiracetam | None | 26 | $727 | $28 |
| Amitriptyline | None | 13 | $706 | $54 |
| Divalproex | None | 16 | $685 | $43 |
| Oxybutynin Chloride Er | None | 14 | $649 | $46 |
| Clopidogrel | None | 38 | $626 | $16 |
| Baclofen | None | 11 | $501 | $46 |
| Escitalopram | None | 24 | $419 | $17 |
| Oxcarbazepine | None | 15 | $410 | $27 |
| Tizanidine | None | 24 | $388 | $16 |
| Nortriptyline | None | 11 | $257 | $23 |
| Clonazepam | None | 11 | $243 | $22 |
| Trazodone | None | 12 | $221 | $18 |
| Pramipexole Dihydrochloride | None | 11 | $217 | $20 |
| Lorazepam | None | 14 | $201 | $14 |
| Prednisone | None | 16 | $191 | $12 |
| Topiramate | None | 11 | $183 | $17 |
| Tramadol | None | 17 | $75 | $4 |
| Diazepam | None | 12 | $43 | $4 |
2018: 31 drugs
| Lyrica | 83 | $58,570 | $706 |
| Aptiom | 12 | $32,080 | $2,673 |
| Neupro | 16 | $20,828 | $1,302 |
| Carbidopa-Levodopa Er | 47 | $4,133 | $88 |
| Carbidopa-Levodopa | 73 | $3,680 | $50 |
| Gabapentin | 116 | $2,928 | $25 |
| Duloxetine | 33 | $2,199 | $67 |
| Mirtazapine | 42 | $1,775 | $42 |
| Memantine | 16 | $1,419 | $89 |
| Divalproex | 26 | $947 | $36 |
| Mycophenolate Mofetil | 11 | $803 | $73 |
| Donepezil | 51 | $728 | $14 |
| Levetiracetam | 20 | $651 | $33 |
| Amitriptyline | 22 | $637 | $29 |
| Quetiapine | 35 | $616 | $18 |
| Atorvastatin | 25 | $537 | $21 |
| Trazodone | 30 | $520 | $17 |
| Clopidogrel | 27 | $518 | $19 |
| Nortriptyline | 28 | $476 | $17 |
| Primidone | 19 | $446 | $23 |
| Propranolol | 25 | $436 | $17 |
| Baclofen | 18 | $375 | $21 |
| Buspirone | 11 | $330 | $30 |
| Oxcarbazepine | 12 | $310 | $26 |
| Escitalopram | 25 | $280 | $11 |
| Clonazepam | 13 | $172 | $13 |
| Lorazepam | 32 | $169 | $5 |
| Zonisamide | 12 | $152 | $13 |
| Prednisone | 12 | $151 | $13 |
| Cyclobenzaprine | 11 | $137 | $12 |
| Diazepam | 18 | $53 | $3 |
2017: 24 drugs
| Lyrica | 75 | $39,674 | $529 |
| Carbidopa-Levodopa Er | 53 | $3,268 | $62 |
| Duloxetine | 40 | $2,919 | $73 |
| Sumatriptan | 11 | $2,887 | $262 |
| Sumatriptan | 15 | $2,017 | $134 |
| Memantine | 17 | $1,636 | $96 |
| Carbidopa-Levodopa | 38 | $1,536 | $40 |
| Gabapentin | 88 | $1,503 | $17 |
| Levetiracetam | 32 | $834 | $26 |
| Nortriptyline | 50 | $830 | $17 |
| Donepezil | 66 | $790 | $12 |
| Divalproex | 25 | $691 | $28 |
| Quetiapine | 28 | $590 | $21 |
| Bupropion Hcl Sr | 32 | $543 | $17 |
| Atorvastatin | 31 | $472 | $15 |
| Escitalopram | 46 | $471 | $10 |
| Amitriptyline | 16 | $396 | $25 |
| Clopidogrel | 23 | $274 | $12 |
| Trazodone | 29 | $197 | $7 |
| Baclofen | 12 | $193 | $16 |
| Mirtazapine | 11 | $184 | $17 |
| Topiramate | 16 | $169 | $11 |
| Prednisone | 11 | $96 | $9 |
| Lorazepam | 15 | $78 | $5 |
2016: 14 drugs
| Tegretol Xr | 12 | $2,286 | $190 |
| Duloxetine | 15 | $1,866 | $124 |
| Gabapentin | 75 | $1,472 | $20 |
| Carbidopa-Levodopa Er | 16 | $810 | $51 |
| Carbidopa-Levodopa | 23 | $683 | $30 |
| Donepezil | 26 | $328 | $13 |
| Nortriptyline | 13 | $324 | $25 |
| Atorvastatin | 17 | $317 | $19 |
| Escitalopram | 17 | $206 | $12 |
| Fluoxetine | 11 | $201 | $18 |
| Topiramate | 11 | $160 | $15 |
| Oxcarbazepine | 11 | $151 | $14 |
| Lorazepam | 14 | $102 | $7 |
| Prednisone | 11 | $76 | $7 |
2015: 5 drugs
| Gabapentin | 72 | $3,544 | $49 |
| Carbidopa-Levodopa Er | 25 | $2,697 | $108 |
| Tegretol Xr | 12 | $2,131 | $178 |
| Carbidopa-Levodopa | 27 | $1,156 | $43 |
| Donepezil | 17 | $444 | $26 |
2014: 11 drugs
| Namenda | 25 | $23,181 | $927 |
| Gabapentin | 89 | $5,361 | $60 |
| Carbidopa-Levodopa Er | 27 | $2,818 | $104 |
| Phenytoin Sodium Extended | 11 | $565 | $51 |
| Nortriptyline | 26 | $334 | $13 |
| Hydrocodone-Acetaminophen | 13 | $314 | $24 |
| Prednisone | 11 | $269 | $24 |
| Lorazepam | 25 | $213 | $9 |
| Hydromorphone | 11 | $198 | $18 |
| Diazepam | 18 | $182 | $10 |
| Amitriptyline | 11 | $146 | $13 |
2013: 11 drugs
| Namenda | 16 | $11,146 | $697 |
| Sumatriptan | 19 | $10,972 | $577 |
| Lyrica | 12 | $4,331 | $361 |
| Gabapentin | 69 | $3,251 | $47 |
| Carbidopa-Levodopa | 15 | $1,120 | $75 |
| Carbidopa-Levodopa Er | 13 | $843 | $65 |
| Lorazepam | 22 | $232 | $11 |
| Hydrocodone-Acetaminophen | 14 | $207 | $15 |
| Amitriptyline | 16 | $186 | $12 |
| Diazepam | 16 | $156 | $10 |
| Nortriptyline | 11 | $127 | $12 |
Money from drug and device companies
$19,931 in 2025
| 2025 | 4 | 20 | $17,350 | $19,931 |
| 2024 | 2 | 26 | $16,025 | $17,663 |
| 2023 | 3 | 4 | None | $134 |
| 2022 | 2 | 2 | None | $107 |
| 2021 | 12 | 17 | $1,695 | $2,019 |
| 2020 | 9 | 12 | $1,130 | $1,409 |
| 2019 | 10 | 28 | None | $698 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Lilly USA | Kisunla | $12,436 | 6 payments
|
| Eisai | Leqembi | $7,441 | 12 payments
|
| Eli Lilly and | Emgality | $29 | 1 payment
|
| Abbvie | Vyalev | $26 | 1 payment
|
See all 20 published payments
| Eisai | Consulting · 2025-12-03 | Leqembi | $825 |
| Abbvie | Meals · 2025-09-11 | Vyalev | $26 |
| Eisai | Travel · 2025-07-23 | Leqembi | $558 |
| Eisai | Travel · 2025-07-19 | Leqembi | $310 |
| Eisai | Paid to speak or teach · 2025-07-17 | Leqembi | $3,300 |
| Eisai | Travel · 2025-07-17 | Leqembi | $124 |
| Eisai | Paid to speak or teach · 2025-07-17 | Leqembi | $1,375 |
| Eisai | Meals · 2025-07-17 | Leqembi | $120 |
| Lilly USA | Consulting · 2025-06-16 | Kisunla | $9,375 |
| Lilly USA | Consulting · 2025-06-16 | Kisunla | $2,200 |
| Lilly USA | Travel · 2025-06-06 | None | $177 |
| Lilly USA | Meals · 2025-06-06 | Kisunla | $176 |
| Lilly USA | Travel · 2025-06-06 | None | $191 |
| Lilly USA | Meals · 2025-06-06 | Kisunla | $317 |
| Eisai | Travel · 2025-06-05 | Leqembi | $343 |
| Eisai | Consulting · 2025-05-09 | Leqembi | $275 |
| Eli Lilly and | Meals · 2025-04-06 | Emgality | $29 |
| Eisai | Meals · 2025-04-06 | None | $66 |
| Eisai | Meals · 2025-04-05 | None | $28 |
| Eisai | Meals · 2025-02-20 | Leqembi | $118 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $17,663
| Eisai | Leqembi | $17,585 | 25 payments
|
| Lilly USA | Amyvid | $78 | 1 payment
|
2023: $134
| Argenx US | Vyvgart | $77 | 1 payment
|
| AbbVie | Qulipta | $35 | 2 payments
|
| Alexion Pharmaceuticals | Soliris | $22 | 1 payment
|
2022: $107
| Biogen | Vumerity | $74 | 1 payment
|
| Alexion Pharmaceuticals | Soliris | $33 | 1 payment
|
2021: $2,019
| Biogen | Tysabri | $1,737 | 3 payments
|
| Teva Pharmaceuticals USA | Ajovy | $80 | 3 payments
|
| Kyowa Kirin | Nourianz | $40 | 2 payments
|
| Lilly USA | Emgality | $23 | 1 payment
|
| ACADIA Pharmaceuticals | Nuplazid | $21 | 1 payment
|
| Novartis Pharmaceuticals | Kesimpta | $21 | 1 payment
|
| Merz Pharmaceuticals | Xeomin | $20 | 1 payment
|
| Alexion Pharmaceuticals | Soliris | $19 | 1 payment
|
| Biohaven Pharmaceuticals | Nurtec Odt | $19 | 1 payment
|
| Ucb | Briviact | $15 | 1 payment
|
| CSL Behring | Hizentra | $13 | 1 payment
|
| Sunovion Pharmaceuticals | Kynmobi | $11 | 1 payment
|
2020: $1,409
| Biogen | None | $1,130 | 1 payment
|
| Alexion Pharmaceuticals | Soliris | $149 | 4 payments
|
| Ucb | Briviact | $29 | 1 payment
|
| Allergan | Ubrelvy | $25 | 1 payment
|
| ACADIA Pharmaceuticals | Nuplazid | $18 | 1 payment
|
| Kyowa Kirin | Nourianz | $16 | 1 payment
|
| EMD Serono | Mavenclad | $15 | 1 payment
|
| Supernus Pharmaceuticals | Trokendi Xr | $15 | 1 payment
|
| Sunovion Pharmaceuticals | Aptiom | $12 | 1 payment
|
2019: $698
| Alexion Pharmaceuticals | Soliris | $167 | 2 payments
|
| EMD Serono | Mavenclad | $145 | 9 payments
|
| Amgen | Aimovig | $127 | 2 payments
|
| Ucb | Briviact | $117 | 4 payments
|
| Sunovion Pharmaceuticals | Aptiom | $41 | 5 payments
|
| Pfizer | Lyrica | $28 | 2 payments
|
| Merz North America | Xeomin | $28 | 1 payment
|
| Allergan | Botox | $19 | 1 payment
|
| Amneal Pharmaceuticals | Rytary | $15 | 1 payment
|
| Supernus Pharmaceuticals | Trokendi Xr | $13 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novartis Pharmaceuticals Corporation · A Single-Arm, Prospective, Multicentre, Open-Label Study To Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate Or Fingolimod Therapy · 2021 | Their institution | $59,743 |
| Novartis Pharmaceuticals Corporation · A Single-Arm, Prospective, Multicentre, Open-Label Study To Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate Or Fingolimod Therapy · 2022 | Their institution | $52,901 |
| Novartis Pharmaceuticals Corporation · A Single-Arm, Prospective, Multicentre, Open-Label Study To Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate Or Fingolimod Therapy · 2023 | Their institution | $1,500 |
| Novartis Pharmaceuticals Corporation · A Single-Arm, Prospective, Multicentre, Open-Label Study To Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate Or Fingolimod Therapy · 2020 | Their institution | $228 |
Professional record
- NPI
- 1265618995
- Licence
- CA A113308California A113308: Current · expires 2028-03-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Neurology (2084N0400X); Federal specialty code 2084N0600X (2084N0600X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2008-01-11
- NPI last updated
- 2020-05-29
- NPI record certified
- 2020-05-29
This is when the NPI record was last certified, not a medical board exam.